A Study of the LVIVO-TaVec122 Product in Subjects With Relapsed/Refractory B-cell Malignancies

Starting soon · Phase 1

Conditions studied: Relapsed/Refractory B-cell Malignancies

In brief

This is a single-arm, open-label and dose-escalation clinical study to evaluate the LVIVO-TaVec122 product in adult subjects with Relapsed/Refractory B-cell Malignancies.

Key facts

Study ID

NCT07628582

Run by

The First Affiliated Hospital with Nanjing Medical University

People needed

48

Starts

2026-09-15

Expected to finish

2030-09-30

Last updated by the study team

2026-06-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects voluntary agreement to provide written informed consent.
• Age ≥ 18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• At least one evaluable tumor lesion.
• Relapsed and/or refractory Non-Hodgkin Lymphoma (NHL) , and relapsed and/or refractory Chronic Lymphocytic Leukemia (CLL) with treatment indications.
• Clinical laboratory values meet screening visit criteria.
• Adequate organ function.

You may not qualify if…

• Prior antitumor therapy with insufficient washout period.
• Prior treatment with allo-Hematopoietic stem cell transplantation (HSCT) or gene therapies.
• Patients who are positive for hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), and human immunodeficiency virus antibody (HIV-Ab).
• Known life-threatening allergic reaction, hypersensitivity reaction, or intolerance to study drug excipients and related excipients, including but not limited to Human Albumin, or those with a history of severe allergic reactions in the past (such as hypersensitivity reactions, or those with severe immune-related reactions such as the need for glucocorticoids to prevent anaphylaxis as assessed by the investigator).
• Female subjects who were pregnant, breastfeeding.
• Any condition deemed by the investigator as rendering the subject unsuitable for participation in this study.

Where it is running

• The First Affiliated Hospital with Nanjing Medical University — Nanjing, Jiangsu, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.